Wetenschappelijk jaaroverzicht 2012 - Catharina Ziekenhuis
Wetenschappelijk jaaroverzicht 2012 - Catharina Ziekenhuis
Wetenschappelijk jaaroverzicht 2012 - Catharina Ziekenhuis
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Grouls RJ<br />
An electronic system to document reasons for medication discontinuation and to flag<br />
unwanted represcriptions in geriatric patients<br />
Linden CM van der*, Jansen PA, Marum RJ van, Grouls RJ*, Egberts TC, Korsten EH*<br />
Drugs Aging. <strong>2012</strong> Dec;29(12):957-62.. Epub <strong>2012</strong> Nov 10<br />
Voor abstract zie: Geriatrie - Linden CM van der<br />
Impactfactor: 2.671<br />
Grouls RJ<br />
Dose accuracy of new versus used Novopen 4 insulin pens<br />
Yucel H*, Taks M*, Menheere P, Grouls R*, Bravenboer B*<br />
Diabetes Technol Ther. <strong>2012</strong> Sep;14(9):810-2. Epub <strong>2012</strong> Aug 6<br />
Voor abstract zie: Inwendige geneeskunde - Yucel H<br />
Impactfactor: 1.931<br />
Harmsze AM<br />
Anafylaxie na ijzerdextraan bij een zwangere vrouw. [Anaphylaxis after iron dextran<br />
administration in a pregnant woman]<br />
Kortenhorst MS*, Harmsze AM*, Hasaart TH*<br />
Ned Tijdschr Geneeskd. <strong>2012</strong>;156(48):A5264<br />
Voor abstract zie: Gynaecologie - Kortenhorst MS<br />
Impactfactor: --<br />
Harmsze AM<br />
The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding<br />
events in patients undergoing elective coronary stenting<br />
Harmsze AM*, Werkum JW, Hackeng CM van, Ruven HJ, Kelder JC, Bouman HJ,<br />
Breet NJ, Berg JM ten, Klungel OH, Boer A de, Deneer VH<br />
Pharmacogenet Genomics. <strong>2012</strong> Mar;22(3):169-75<br />
OBJECTIVES: To investigate the impact of genotypes on the basis of the loss-of-function<br />
variant CYP2C19*2 and the gain-of-function variant CYP2C19*17 on on-treatment platelet<br />
reactivity and on the occurrence of Thrombolysis in Myocardial Infarction (TIMI) major<br />
bleedings in 820 clopidogrel-treated patients who underwent elective coronary stenting.<br />
METHODS: On-treatment platelet reactivity was quantified using ADP-induced light<br />
transmittance aggregometry (LTA) and the VerifyNow P2Y12 assay. Postdischarge TIMI major<br />
bleedings within 1 year after enrollment were recorded.<br />
RESULTS: In total, 25 major bleedings (3.0% of the study population) were observed. Patients<br />
with the CYP2C19*1/*17 and *17/*17 diplotypes exhibited a lower magnitude of platelet<br />
reactivity as compared with patients with the CYP2C19*1/*1 diplotype (for the light<br />
transmittance aggregometry-adjusted mean difference: -5.8%, 95% confidence interval: -9.6<br />
to -2.1, P=0.002). Patients with the *1/*17 and *17/*17 genotype had a 2.7-fold increased<br />
risk in the occurrence of major bleedings [adjusted hazard ratio: 2.7, 95% confidence<br />
interval: 1.1-7.0, P=0.039]. The diplotypes *2/*17, *1/*2, and *2/*2 exhibited higher<br />
ontreatment platelet reactivity as compared with the wild type (P
Change language